Smooth muscle actin (SMA)-negative uninodular plexiform fibromyxoma: case report of a challenging atypical presentation of a rare gastric mesenchymal tumor in a 25-year-old female Authors: Armin Jarosch, Tomasz Dziodzio, Brigitta Globke, Robert Öllinger, Frederik Maximilian Schäfer, Kathrin Hauptmann, Sabina Niyazova, Anne Flörcken, David Horst, Abbas Agaimy, Simon Schallenberg Published: 2026 ABSTRACT AbstractBackgroundPlexiform fibromyxoma (PFM) is an uncommon, benign mesenchymal tumor typically arising in the gastric antrum and usually characterized by a multinodular, plexiform growth pattern of smooth muscle actin (SMA)-expressing myofibroblastic-like cells. Rare variants with uninodular architecture and absence of SMA expression pose significant diagnostic challenges, as they may mimic gastrointestinal stromal tumors (GISTs) and require comprehensive histopathologic, immunohistochemical, and molecular evaluation to avoid misdiagnosis and inappropriate therapy.Case DescriptionHere, we present a case of PFM with a rare uninodular architecture, complete absence of SMA expression and no detectable MALAT1-GLI1 translocation in a 25-year-old female with unremarkable laboratory work-up (hemoglobin 13.9 g/dL, normal blood count and biochemistry) presented with diffuse upper abdominal discomfort and a palpable epigastric mass noted on self-examination. Physical examination revealed a firm, non-tender mid-abdominal mass without peritonism. The tumor measured 13 cm and was discovered as a palpable mass on self-examination during diagnostic work-up for upper abdominal discomfort. Histologically, the lesion was composed of bland spindle cells embedded in a loose myxoid stroma, lacking the classic multinodular configuration. Immunohistochemistry was negative for SMA, DOG1, S100, CD34, desmin, and anaplastic lymphoma kinase (ALK). Molecular analysis revealed no pathogenic mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) and no detectable gene fusions. The final diagnosis was most consistent with uninodular PFM as diagnosed by exclusion.ConclusionsThis case highlights the importance of an early multimodal diagnostic work-up (including histology, immunohistochemistry, and next-generation sequencing) in atypical gastric mesenchymal tumors, e.g., PFMs, to avoid misdiagnosis as a GIST and inappropriate tyrosine kinase inhibitor therapy. Complete surgical resection with negative margins using stomach-preserving techniques is curative and associated with an excellent prognosis.Keywords: Plexiform fibromyxoma (PFM), case report, smooth muscle actin-negative (SMA-negative), uninodular variant, gastrointestinal stromal tumor mimicker (GIST mimicker) Highlight box Key findings • We report an unusual variant of plexiform fibromyxoma (PFM) featuring uninodular architecture rather than the typical multinodular plexiform pattern, with complete absence of smooth muscle actin (SMA) expression. • Molecular testing revealed no KIT/platelet-derived growth factor receptor alpha (PDGFRA) alterations or translocations involving GLI1 or MALAT1, underscoring the genetic heterogeneity of PFM. What is known and what is new? • PFM is an uncommon benign gastric mesenchymal neoplasm classically displaying multinodular plexiform growth, SMA expression, and lack of KIT/PDGFRA mutations. • Our case broadens the morphologic and immunophenotypic spectrum of PFM, showing that uninodular configuration and absent SMA staining do not exclude the diagnosis when other features are compatible. What is the implication, and what should change now? • Pathologists should be aware that PFM can present with atypical features beyond the classical description, requiring careful exclusion of other mesenchymal neoplasms through multimodal diagnostics. • Correct identification of atypical PFM presentations is essential to prevent misclassification as gastrointestinal stromal tumor, thereby avoiding inappropriate tyrosine kinase inhibitor treatment or unnecessarily extensive surgical intervention. • Complete excision with negative margins remains the therapeutic standard, given the benign behavior of PFM regardless of morphologic variation. Introduction Plexiform fibromyxoma (PFM) is a rare, benign mesenchymal neoplasm of the gastrointestinal tract, historically described under various terms such as fibromyxoma, myxoma, or more recently as plexiform angiomyxoid myofibroblastic tumor (1,2). Since its initial characterization in 2007 (2), several case series have expanded the clinicopathologic understanding of PFM. However, fewer than 200 cases have been reported in the literature to date (3,4). Patients are typically diagnosed between 7 and 75 years of age, with a median age of 41–51 years, and both sexes are affected equally (1,3). The tumor predominantly arises in the gastric antrum (1,3), particularly in the pyloric region, although rare cases involving other gastric regions, the esophagus, intestine, and gallbladder have also been described (5-11). Clinical symptoms are often nonspecific and may include ulceration, abdominal distension, gastrointestinal bleeding, and anemia (1). In some instances, PFM is detected incidentally during imaging or endoscopic procedures (3). Histologically, PFM is characterized by bland tumor cells with ovoid to spindle-shaped nuclei and lightly eosinophilic cytoplasm arranged in a multinodular, plexiform architecture, embedded within a fibromyxoid stroma with a prominent arborizing capillary network (1,3,12). The tumor frequently exhibits an infiltrative margin toward the mucosa or muscularis propria (1). However, rare variants limited to the mucosa/submucosa have been reported (13). Features such as cellular atypia, increased mitotic activity, or necrosis are generally absent (3). The typical immunophenotype includes strong positivity for smooth muscle actin (SMA) and vimentin, and negativity for CD117 (KIT), DOG1, CD34, desmin, S100, and anaplastic lymphoma kinase (ALK). This profile aids in distinguishing PFM from histologic mimickers such as myxoid variants of gastrointestinal stromal tumors (GISTs), inflammatory fibroid polyps (IFPs), myxoid leiomyomas, plexiform neurofibromas, schwannomas, and inflammatory myofibroblastic tumors (IMTs) (1). In contrast to PFM, GISTs demonstrate strong expression of DOG1 and CD117, and frequently harbor activating mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA), typically involving exons 11 and 9 for KIT and exon 18 for PDGFRA (1). Moreover, a prominently myxoid stroma is rare among GISTs and occurs more frequently in the epithelioid PDGFRA-mutated subtype (14). GISTs generally form solitary, well-demarcated masses and lack the distinctive plexiform intramural growth pattern of PFM (1,14). The pathogenesis of PFM remains incompletely understood, but differs clearly from that of GIST, given the absence of canonical KIT or PDGFRA mutations (3). In a subset of cases, alterations involving the GLI1 gene have been reported, indicating activation of the Hedgehog signaling pathway, which plays an important role in gastrointestinal tract development (3,15-17). IFPs, another important differential diagnosis, are characterized by CD34 positivity and a perivascular, concentrically layered onion-skin growth pattern (18). These lesions frequently exhibit PDGFRA mutations, most often in exon 12 (19,20). In contrast, PFM lacks CD34 expression and PDGFRA mutations. Myxoid leiomyomas may exhibit tortuous, plexiform growth and SMA positivity (1,21); however, they are typically well-circumscribed and composed of fascicles of tumor cells closely resembling normal smooth muscle, with uniform, blunt-ended nuclei and dense eosinophilic cytoplasm. These tumors also express additional smooth muscle markers such as desmin and h-caldesmon (21). Plexiform neurofibromas and schwannomas, both of neural origin, are typically distinguishable by their characteristic histomorphology and consistently strong, diffuse expression of S100 and SOX10. IMTs may express ALK in a subset of cases, especially in younger patients, and often harbor ALK gene rearrangements. They typically co-express SMA and desmin (22). Beyond this core immunoprofile, additional markers may assist in the evaluation of diagnostically challenging mesenchymal gastric tumors. Nuclear expression of STAT6 is a highly sensitive and specific indicator of solitary fibrous tumor (SFT), reflecting the underlying NAB2-STAT6 gene fusion, whereas non-SFT mesenchymal neoplasms generally lack strong nuclear STAT6 staining (23-25). Loss of SDHB expression identifies SDH-deficient GIST, a subset of KIT/PDGFRA-wild-type gastric GISTs that typically occur in children and young adults and show limited response to standard tyrosine kinase inhibitor therapy (26,27). Desmoid-type fibromatosis, in contrast, is strongly associated with activating CTNNB1 mutations and aberrant nuclear accumulation of β-catenin, which serves as a useful immunohistochemical marker (28). Nevertheless, the histological and immunophenotypic features of PFM are not always consistent. Rare cases, such as the one presented here, an uninodular architecture with SMA negativity, show atypical features, complicating the diagnostic process. Thus, a complete diagnostic approach integrating histopathology, immunohistochemistry, and molecular testing is essential for accurate diagnosis and appropriate clinical management. We present this article in accordance with the CARE reporting checklist (available at https://acr.amegroups.com/article/view/10.21037/acr-2025-295/rc). Case presentation A 25-year-old female initially presented to an emergency department with diffuse mid-abdominal pain and progressive abdominal distension. Also, she noted a newly palpable epigastric mass during self-examination. Routine laboratory tests were unremarkable, and there was no evidence of anemia or systemic inflammation. Subsequent esophagogastroduodenoscopy showed no intraluminal abnormalities. The patient was then referred to the Charité-Universitätsmedizin Berlin, a tertiary care center, for further evaluation. On clinical evaluation in our outpatient clinic, we saw a very slim young woman with a firm, sharply demarcated lesion palpable through the abdominal wall, without tenderness or signs of peritonism, and with otherwise normal vital parameters and general condition. There was no history of prior abdominal surgery, no regular medication, no known personal or family history of malignancy or hereditary tumor syndromes, and the psychosocial history was unremarkable. Abdominal ultrasonography and contrast-enhanced computed tomography (CT) revealed a well-circumscribed, non-homogeneous mass measuring 13 cm in greatest dimension, arising from the antral region of the gastric wall (Figure 1). The lesion exhibited smooth, regular borders without radiological evidence of local infiltration, suspicious for, but not completely typical of, a GIST. Dynamic contrast administration showed a gradually heterogeneous enhancement pattern, and the absence of significant diffusion restriction on magnetic resonance imaging (MRI) further suggested a benign-appearing, though indeterminate, mesenchymal lesion. As the initial punch-biopsy could not clarify the entity of the lesion, surgical resection was recommended by our interdisciplinary tumor conference for sarcomas. Preoperative laboratory work-up, including complete blood count, basic biochemistry, and coagulation studies, was unremarkable (Table 1). Appearance in diagnostic imaging. Pre-operative computed tomography scan showing tumor with non-homogenous tissue and an indicative connection to the gastric antrum. Table 1Preoperative laboratory findingsParametersPreoperative valuesBiochemistry Sodium (mmol/L)137 Potassium (mmol/L)3.9 Magnesium (mmol/L)0.91 Iron (µmol/L)6.3 TSH basal (mU/L)1.55Blood count Hemoglobin (g/dL)13.9 Hematocrit (L/L)0.404 MCV (fL)89.6 MCH (pg)30.8 MCHC (g/dL)34.4 Erythrocytes (/pL)4.5 Leukocytes (/nL)5.59 Platelets (/nL)214 Neutrophils absolute (/nL)3.62 Lymphocytes absolute (/nL)1.22 Monocytes absolute (/nL)0.59 Eosinophils absolute (/nL)0.04 Basophils absolute (/nL)0.03Coagulation INR0.99 Quick (%)100 aPTT (s)34.6aPTT, activated partial thromboplastin time; INR, international normalized ratio; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; TSH, thyroid-stimulating hormone. Preoperative laboratory findings aPTT, activated partial thromboplastin time; INR, international normalized ratio; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; TSH, thyroid-stimulating hormone. A solitary, solid tumor adjacent to the gastric antrum, with no invasion of other tissues or evidence of peritoneal dissemination was identified laparoscopically. The tumor was then resected en bloc via mini-laparotomy with a scarce tangential gastric resection using a stapling device. Frozen section showed negative resection margins, and the integrity of the gastric wall was preserved. This limited, tangential gastric resection was selected to achieve complete tumor removal with negative margins while maintaining gastric function, based on the intraoperative impression of a benign, well-demarcated lesion. The postoperative course was uneventful. No intra-abdominal drains were placed. On postoperative day 1, the patient experienced mild postoperative nausea and vomiting, but oral intake could be advanced without complications thereafter. She was discharged home in good general condition on postoperative day 3. Macroscopic examination of the resected specimen revealed a well-demarcated, yellowish, myxoid tumor (Figure 2). Although the lesion was anatomically adjacent to the stomach, histological assessment confirmed that the gastric wall was free of tumor infiltration. Microscopically, the lesion consisted of a relatively hypocellular proliferation of uniform spindle-shaped cells with vesicular nuclei and elongated eosinophilic cytoplasm. The stroma was loosely textured and myxoid, containing slit-like capillaries and scattered inflammatory infiltrates (Figure 3). Immunohistochemically, the tumor cells showed a complete absence of staining for SMA, DOG1, S100, CD34, desmin, and ALK (Figure 4). Additional immunohistochemical stains demonstrated a lack of STAT6 expression, absence of nuclear β‑Catenin accumulation, and retained SDHB expression (Figure 5), effectively excluding SFT, desmoid‑type fibromatosis, and SDH‑deficient mesenchymal neoplasms. Comprehensive molecular profiling, including targeted next-generation sequencing using the Agilent SureSelect XT HS2 custom panel (Agilent Technologies, Santa Clara, CA, USA), revealed no pathogenic alterations in any genes, including PDGFRA and KIT. In addition, RNA-based fusion transcript analysis using the Archer FusionPlex Sarcoma v2 panel (Integrated DNA Technologies, Coralville, IA, USA) identified no gene rearrangements. In light of the absence of a multinodular architecture and based on the combined histological, immunophenotypic, and molecular findings, the tumor was best classified as a uninodular PFM. Macroscopic appearance. The tumor appears sectioned, uninodular, with a homogeneous, yellowish-white cut surface (A). The inset displays a close-up of the cut surface, showing no necrosis or hemorrhage (B). Microscopic appearance. (A) Overview of the well demarked uninodular tumor. (B-D) Detail of the relatively hypocellular proliferation (B) of uniform spindle cells with vesicular nuclei and elongated eosinophilic cytoplasm (C) with a loose and myxoid background, punctuated by slit-like vessels and scattered inflammatory infiltrates (D). Hematoxylin and eosin staining; scale bar: A, 2 mm; B, 100 µm; C, 20 µm; D, 50 µm. Immunohistochemical features. Complete absence of immunohistochemical expression for smooth muscle actin (A), DOG1 (B), CD34 (C), S100 (D), desmin (E), ALK (F). Scale bar: 100 µm. ALK, anaplastic lymphoma kinase; DOG1, discovered on gastrointestinal stromal tumor-1. Immunohistochemical features. Complete absence of immunohistochemical expression of nuclear β-catenin (A) and STAT6 (B), with retained expression of SDHB (C). Scale bar: A, 100 µm; B, 100 µm; C, 20 µm. SDHB, Succinate Dehydrogenase Subunit B; STAT6, Signal Transducer and Activator of Transcription 6. After discussion of the definitive pathology and confirmation of a benign entity without adverse histological features, no structured oncological follow-up program was recommended. The patient was contacted by telephone approximately 12 months post-resection and reported sustained well-being without gastrointestinal symptoms or clinical concerns, consistent with current evidence for the benign behavior of PFM. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Declaration of Helsinki and its subsequent amendments. Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal. Discussion PFM represents an exceedingly rare mesenchymal neoplasm, with only 130 cases reported between 2007 and 2020 (8). While classical PFM typically exhibits multinodular, plexiform architecture with SMA positivity, our case represents an exceptional deviation from these hallmarks, showing both uninodular growth and complete absence of SMA expression in a 13 cm tumor without evidence of gastric wall infiltration. Immunohistochemically, PFM typically expresses vimentin and SMA, while being negative for DOG1, CD117, desmin, CD34, S100, and ALK (1). Nuclear expression of the progesterone receptor has also been reported in some cases (1,4). Although SMA expression is considered characteristic, its absence, as in our case, does not preclude the diagnosis when supported by compatible histological and molecular findings (1). The uninodular architecture and the lack of SMA expression in this case expand the known histomorphologic and immunophenotypic spectrum of PFM. A comprehensive literature update from 2019 (4) reported complete SMA negativity in only 4 of 111 immunohistochemically evaluated cases (3.6%), while vimentin remained positive in all tested cases (100%). Uninodular growth represents an even rarer presentation, with only a single previously documented case with 10 mm that showed slow growth over 4 years (29). The present case is therefore exceptional in demonstrating the coexistence of SMA negativity and uninodular growth in a large 13 cm tumor, representing a diagnostic constellation that substantially increases the risk of misdiagnosis. These atypical features posed a diagnostic challenge and initially raised suspicion for other mesenchymal neoplasms such as GIST, IFP, leiomyoma, plexiform neurofibroma, IMT, or even soft tissue sarcoma. Accurate differential diagnosis relies on a combined evaluation of morphology, immunohistochemistry, and molecular genetics. GISTs, which are significantly more common, typically express CD117 and DOG1 and harbor activating mutations in KIT or PDGFRA (1), features absent in our case. IFPs, while benign and occasionally myxoid, are usually CD34-positive (18,19). Histologically, they show a mixture of inflammatory cells, particularly eosinophils, together with epithelioid to spindled fibroblasts arranged in a characteristic perivascular onion-skin pattern but lack the distinct plexiform architecture of PFM (18). Like PFM, they tend to localize to the gastric antrum, but usually present as intraluminal, pedunculated submucosal polyps (19,20). The vast majority of IFPs harbor activating PDGFRA mutations, which are absent in PFM (19,20). IMTs typically occur in younger individuals and are characterized by ALK expression, frequent ALK or ROS1 rearrangements, and co-expression of SMA and desmin (30). Myxoid leiomyomas, while often morphologically similar, typically express desmin, which was negative in our case. Plexiform neurofibromas and schwannomas are strongly S100 and SOX10-positive and are usually distinguishable based on their neural histomorphology. Molecular analysis plays an increasingly central role in distinguishing PFM from its histologic mimics. A recurrent translocation t(11;12)(q11;q13) involving MALAT1 and GLI1 has been described in 18–38% of PFMs (3,16). Although GLI1 fusions represent a recurrent molecular event in a subset of PFMs, their absence does not exclude the diagnosis and instead highlights the genetic heterogeneity of this entity. Additionally, inactivating mutations of the PTCH1 gene, implicating dysregulation of the Hedgehog signaling pathway, have been reported in a smaller subset (31). While some PFMs harbor MALAT1-GLI1 fusions or rare alterations such as PTCH1 inactivation or GLI1 polysomy (12q13) (16), most PFMs remain molecularly undefined, underscoring marked genetic heterogeneity. Our GLI1-negative tumor exemplifies this group and suggests that alternative genetic or epigenetic mechanisms may contribute to tumor development while maintaining the benign phenotype. The complete absence of SMA expression in the present case raises mechanistic questions regarding myofibroblastic differentiation. SMA expression is largely regulated by TGF-β signaling, which, together with extracellular matrix composition and mechanical stress, promotes stable myofibroblast differentiation with persistent SMA expression (32). Disruption of TGF-β signaling or increased proliferative activity may destabilize this differentiation program (33), potentially explaining the loss of SMA expression. In this context, the selective loss of SMA in our case, combined with marked tumor growth, may reflect microenvironmental or signaling alterations that shift the cellular phenotype from myofibroblastic differentiation toward a more proliferative state. Despite this phenotypic divergence and unusual tumor size, the lesion retained the benign biological behavior characteristic of PFM, highlighting the importance of correlating molecular findings with histological and immunophenotypic features. To date, PFM has not been associated with malignant transformation or metastatic behaviour, even in cases with ulceration or vascular invasion (1). From a clinical perspective, recognizing PFM, particularly in its atypical presentations, is critical to avoid overtreatment. Misinterpretation as GIST could lead to unnecessary administration of tyrosine kinase inhibitors or excessively aggressive surgical management. Preoperative imaging may provide additional clues but remains challenging for definitive diagnosis. Differentiation between PFM and myxoid variants of GIST is often difficult, although several imaging features may raise suspicion. Reported PFMs frequently appear as well-circumscribed intramural or extraluminal mass with heterogeneous internal structure and gradual progressive enhancement on contrast‑enhanced CT or MRI, reflecting the myxoid tumor stroma. In contrast, GISTs more commonly present as larger, welldemarcated masses with a solid peripheral or rimlike enhancement surrounding areas of necrosis or cystic degeneration (34-36). In the present case, imaging revealed a large, well-circumscribed, heterogeneous mass in the gastric antrum with gradual enhancement and no marked diffusion restriction. Although these findings suggested a benign lesion, uncertainty regarding malignancy remained. Combined with endoscopic ultrasound findings, such imaging characteristics may prompt consideration of benign myxoid mesenchymal tumors such as PFM while emphasizing the need for definitive histopathologic and molecular confirmation. Across reported cases spanning more than a decade, PFM has consistently demonstrated benign biological behavior, with no documented recurrences or metastases following complete resection (3,4,8). Comprehensive reviews describe follow-up periods with median durations of 15–52 months in cohorts of 55–130 patients, all of whom experienced uneventful clinical outcomes (4,8). Current evidence therefore supports stomach-preserving surgical approaches as the treatment of choice, ranging from local wedge resection to limited distal gastrectomy, provided that negative margins are achieved (1,8,37). In the present case, intraoperative assessment demonstrated a wellcircumscribed, extraluminal mass without invasion of the gastric wall or adjacent structures. Frozen section analysis confirmed negative margins, allowing a tangential wedge resection instead of radical gastrectomy and aligning with current recommendations to avoid overtreatment of this benign entity. No recurrence was observed during follow-up time, consistent with the favorable clinical course described for PFM. Nevertheless, given its rarity, the full biological potential of PFM remains uncertain. Until more data are available, complete surgical resection remains the standard of care (17). Conclusions This case illustrates the unique coexistence of uninodular architecture and complete absence of SMA expression in a massive PFM, expanding the recognized histological and immunophenotypic spectrum of this benign gastric tumor. It emphasizes the necessity of a multimodal diagnostic approach integrating histopathology, immunoprofiling, and molecular testing to ensure accurate diagnosis and avoid overtreatment. Given the absence of recurrence or metastatic potential in reported cases, complete surgical excision with negative margins remains the treatment of choice. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Declaration of Helsinki and its subsequent amendments. Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal. Footnotes Reporting Checklist: The authors have completed the CARE reporting checklist. Available at https://acr.amegroups.com/article/view/10.21037/acr-2025-295/rc Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://acr.amegroups.com/article/view/10.21037/acr-2025-295/coif). The authors have no conflicts of interest to declare. References Available at https://acr.amegroups.com/article/view/10.21037/acr-2025-295/prf Supplementary Materials The article’s supplementary files as